Stephen Lockhart | Director, Senior Consultant
HURST GRANGE ASSOCIATES
I qualified in Medicine from the University of Oxford in 1980. After working around the UK in hospital medicine and research, I joined the pharmaceutical industry in 1986. I am a Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. For over 30 years I have been engaged in global vaccine clinical R&D across all phases, in Lederle, Wyeth, Emergent BioSolutions, sanofi-pasteur MSD, and most recently Pfizer. I was involved with bringing some major vaccines to the clinic, including the first pneumococcal and the first meningococcal conjugate vaccines and the first modRNA COVID-19 vaccine, but have also learnt much from less successful developments. I am currently a consultant with Hurst Grange Associates, stephenlockhart@hurstgrangeassociates.co.uk.
Appearances:
Day 2 - Wednesday 15th October @ 15:45
Comparative analysis of regulatory approaches to new arbovirus vaccines across different regions
Significant progress in research on arboviruses and flaviviruses; dengue, tick-borne encephalitis, yellow fever
Evolving landscape of regulatory strategies for clinical trials in vaccine development
Valneva's experience with chikungunya vaccine as a case study in innovative regulatory approaches
Discussion on how regulatory frameworks are adapting to new vaccine technologies and global health challenges
Day 3 - Thursday 16th October @ 13:30
Showcasing & Utilising Established Challenge Models: What can we achieve with these?
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events